PMID: 7843749Jan 1, 1995Paper

Hemodynamic and biochemical effects of the AT1 receptor antagonist irbesartan in hypertension

A H van den MeirackerA J Man In 't Veld


We studied the hemodynamic, neurohumoral, and biochemical effects of the novel angiotensin type 1 (AT1) receptor antagonist irbesartan in 86 untreated patients with essential hypertension on a normal sodium diet. According to a double-blind parallel group trial, patients were randomized to a once-daily oral dose of the AT1 receptor antagonist (1, 25, or 100 mg) or placebo after a placebo run-in period of 3 weeks. Randomization medication was given for 1 week. Compared with placebo, 24-hour ambulatory blood pressure did not change with the 1-mg dose, and it fell (mean and 95% confidence interval) by 7.0 (4.2-9.8)/6.1 (3.9-8.1) mm Hg with the 25-mg dose and by 12.1 (8.1-16.2)/7.2 (4.9-9.4) mm Hg with the 100-mg dose. Heart rate did not change during either dose. With the 25-mg dose, the antihypertensive effect was attenuated during the second half of the recording, and with the 100-mg dose, it was maintained for 24 hours. Baseline values of renin and the antihypertensive response to the 25- and 100-mg doses were well correlated (r = .68, P < .01). Renin did not change with the 1-mg dose, but it rose threefold to fourfold with the 25-mg dose and fourfold to fivefold with the 100-mg dose 4 to 6 hours after administration. With the ...Continue Reading


May 4, 1978·The New England Journal of Medicine·H GavrasD N McKinstry
Dec 1, 1992·American Journal of Hypertension·R R WexlerP B Timmermans
Jan 1, 1992·European Journal of Clinical Pharmacology·M NakashimaM Kanamaru
Dec 1, 1990·The American Journal of Physiology·D W JohnsR M Carey
Apr 21, 1982·The American Journal of Cardiology·G ManciaA Zanchetti
Aug 1, 1981·Kidney International·N K HollenbergD P Harrington

❮ Previous
Next ❯


Apr 29, 1998·Journal of Clinical Pharmacology·M R MarinoH D Uderman
May 20, 1998·Journal of Clinical Pharmacology·M R MarinoK C Lasseter
Oct 6, 1998·European Journal of Pharmacology·C Damase-MichelP Montastruc
Feb 4, 1998·Journal of Chromatography. B, Biomedical Sciences and Applications·S Y ChangR Patel
Jul 28, 2001·European Journal of Clinical Investigation·W KirchJ Schweizer
Aug 11, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Mario Salcedo-AlejosFernando Guerrero-Romero
Jul 27, 1999·Journal of Hypertension·W H Birkenhäger, P W de Leeuw
May 1, 2001·Journal of Hypertension·J P van KatsA H Danser
Jun 14, 2001·Journal of Hypertension·K MalmqvistJ Ostergern
Feb 1, 1997·Journal of Cardiovascular Pharmacology·Y HashimotoS Murata
Feb 25, 1998·Journal of Cardiovascular Pharmacology·F SchmittJ P Grunfeld
Oct 8, 1999·Journal of Cardiovascular Pharmacology·H EbisuN Nakamura
Apr 13, 2001·Journal of Cardiovascular Pharmacology·J RibsteinA Mimran
Nov 18, 1998·Current Opinion in Nephrology and Hypertension·N Perico, G Remuzzi
Sep 1, 1996·Clinical and Experimental Pharmacology & Physiology·B WaeberH R Brunner
Nov 30, 2013·TheScientificWorldJournal·Jacqueline Heger, Klaus-Dieter Schlüter
May 16, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yusuke Ariyoshi, Keigo Mizumoto
Nov 25, 1995·Lancet·C I Johnston
May 1, 1997·Expert Opinion on Investigational Drugs·M Burnier, H R Brunner
Aug 7, 1999·The American Journal of Cardiology·P W de Leeuw
Feb 24, 2001·Journal of Receptor and Signal Transduction Research·M J Robertson
Mar 29, 2002·Diabetes Care·Christine A HoulihanGeorge Jerums
Mar 25, 2006·Thérapie·Philippe GrimbertUNKNOWN APPROVE Study Investigators
Aug 17, 2018·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Brian R Stotter, Michael A Ferguson
Jan 3, 2007·Journal of the Renin-angiotensin-aldosterone System : JRAAS·L M Ruilope
Oct 12, 2018·The Journal of Physiology·E N Bardsley, D J Paterson
Jan 20, 1998·Clinical Pharmacology and Therapeutics·D A SicaN F Ford
Aug 20, 2005·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Michael BoschmannJens Jordan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.